Fusion Protein for Treatment of Inflammatory Diseases

Abstract

Researchers at the University of California, Davis have developed a plant-based, fusion protein for use in the treatment of inflammatory diseases.

Full Description

Inflammatory diseases - such as alpha-1 anti-trypsin deficiency (AATD) and cystic fibrosis (CF) – are currently treated using plasma-derived, IV replacement therapies. Although such therapies are safe and effective, they have limitations due to cost, purity specifications, and limited availability. There is a need for a treatment that avoids the complexity and cost of collection, purification, sterilization, preservation and distribution of plasma.

Researchers at the University of California, Davis have developed a plant-based, elafin-fusion protein that can be used as a potential therapeutic to treat patients with inflammatory diseases. This therapeutic provides a cost-effective and stable treatment option for patients who either lack access to plasma-derived, IV replacement therapies or are seeking a lower cost, alternative therapy. The protein is resistant to proteolytic cleavage and oxidation, and has anti-inflammatory properties. Additionally, the therapeutic exhibits human-like glycosylation, has a longer half-life than other treatments and can be delivered via infusion or inhalation.

Applications

•         Protein therapy for inflammatory diseases such as AATD and CF
•         Can be delivered via either infusion or inhalation

Features/Benefits

•         Proteolytic cleavage-resistant
•         Oxidation-resistant
•         Improved stability
•         Lower manufacturing and clinical costs compared to current treatment options
•         Extended serum half-life
•         Anti-inflammatory properties
•         Delivery by infusion or inhalation

Patent Status

Related Materials